Antitrust Concerns Don’t Cloud Merck-Schering Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck and Schering expect limited divestments, including one of their two products in development for colorectal cancer.
You may also be interested in...
Shared Strengths: The Merck And Schering Pipelines
Merck’s acquisition of Schering-Plough brings much-needed late-stage assets, including potential blockbusters like TRA and bocepravir; the combined pipelines also strengthens existing footholds in neuroscience and respiratory drugs.
A Goliath Grows: Pfizer To Buy Wyeth For $68 Billion
Pfizer aims to acquire rival Wyeth in a proposed deal valued at approximately $68 billion, broadening Pfizer's leadership position in the market by creating a drug powerhouse with combined sales of more than $71 billion, based on 2008 revenues
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.